Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9529535

Tissue engineering in urologic surgery.

A Atala
View original source ↗Export metadata ↓

Abstract

The use of nonurologic tissues in the genitourinary tract is common (owing to a lack of a better alternative) despite the known possible adverse effects. Selective cell transplantation is providing a means to engineer genitourinary tissues that may be used for reconstruction. This novel technology involves an interdisciplinary approach, combining techniques of cell biology and materials sciences towards the development of functional tissues or organs. Tissues associated with urology, such as clitoral, cavernosal, urethral, vesical, ureteral, and renal have been created in the laboratory, with varying degrees of function. Cells have also been recently used in patients as bulking agents for the treatment of vesicoureteral reflux and urinary incontinence. As the science of tissue engineering evolves, one can expect a wider application of this technology to the armamentarium of urologic surgery.

Explore related subjects

Cell TransplantationCells, CulturedFetal DiseasesGenetic TherapyHumansInjectionsUrogenital SystemJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Atala. 1998. Tissue engineering in urologic surgery.. https://doi.org/10.1016/s0094-0143(05)70431-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Cell-based gene therapy for the prevention and treatment of cardiac dysfunction.

A substantial need exists for new treatments to prevent and treat cardiac dysfunction. In the 1990s, there was great hope for gene therapy in this regard. Since that time, the focus has switched to cell therapy-in particular, therapy-with the aim of inducing myocardial regeneration. Individually, gene and cell therapies still have substantial promise. Ultimately, however, the convergence of both techniques might be necessary to achieve improvements in cardiac function and more successful clinical outcomes in patients with cardiac dysfunction. This approach has already been adopted for treatment of malignancies. Several gene products are currently being studied, including growth factors and chemokines that can modulate the survival and function of cardiac myocytes following an ischemic event and influence remodeling of the left ventricle. However, several issues remain, including the optimization and characterization of cell types, selection of vectors for gene transfer, and identification of appropriate strategies for delivery. Here, we review the potential and need for cell-based gene therapy for the prevention and treatment of cardiac dysfunction and attempt to discuss the unresolved issues.

Cell Transplantation↗
PubMed2006

Present status and perspectives of cell-based therapies for liver diseases.

In recent years the interest in liver cell therapy has been increasing continuously, since the demand for whole liver transplantations in human beings far outweighs the supply. From the clinical point of view, transplantation of hepatocytes or hepatocyte-like cells may represent an alternative to orthotopic liver transplants in acute liver failure, for the correction of genetic disorders resulting in metabolically deficient states, and for late stage liver disease such as cirrhosis. Although the concept of cell therapy for various diseases of the liver is widely accepted, the practical approach in humans often remains difficult. An international expert panel critically discussed the recent published data on clinical and experimental hepatocyte transplantation and the possible role of stem cells in liver tissue repair. This paper aims to summarise the present status of cell based therapies for liver diseases and to identify areas of future preclinical and clinical research.

Cell Transplantation↗